Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Virus-like particles |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
CAS Number |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.[2][3][4][5]
On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.[6]